Skip to main content
HLB Life Science CO.,LTD. logo

HLB Life Science CO.,LTD. — Investor Relations & Filings

Ticker · 067630 ISIN · KR7067630004 LEI · 9884006PTFB20S9PS149 KO Manufacturing
Open in API
Filings indexed 396 across all filing types
Latest filing 2023-03-23 AGM Information
Country KR South Korea
Listing KO 067630

About HLB Life Science CO.,LTD.

https://www.hlb-lsmc.com/

HLB Life Science is a specialized pharmaceutical and biotechnology firm focused on the development of innovative anti-cancer medications and the manufacturing of medical devices. The company's research and development efforts center on targeted therapies and cell therapies for oncology. In parallel, it develops, manufactures, and distributes in vitro diagnostic (IVD) medical devices and quasi-drugs. The company's portfolio also includes the clinical development of anti-cancer drugs for animals, aiming to provide comprehensive solutions across human and animal health.

Recent filings

Filing Released Lang Actions
[기재정정]주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Correction Report' (정정신고) regarding a previously filed 'Notice of General Meeting of Shareholders' (주주총회소집공고). It specifically details corrections to the financial statements (재무제표) that were originally included as part of the meeting agenda materials. Since this document is an official regulatory filing correcting previously submitted information for a shareholder meeting, it falls under the category of Proxy Solicitation & Information Statement (PSI), as these materials are provided to shareholders to inform them of the agenda and financial status prior to the meeting.
2023-03-23 Korean
사업보고서 (2022.12)
Annual Report Classification · 100% confidence The document is titled '사업보고서' (Business Report) for the 25th fiscal year (2022), which is the standard terminology for an Annual Report in South Korea. It contains comprehensive company information, business overviews, financial history, and management details, consistent with the requirements for a 10-K equivalent filing. FY 2022
2023-03-23 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 100% confidence The document is a 'Report on Ownership of Specific Securities by Executives and Major Shareholders' (임원ㆍ주요주주 특정증권등 소유상황보고서) filed in South Korea. This type of filing is a standard regulatory requirement for major shareholders or insiders to disclose changes in their holdings, which falls under the category of 'Director's Dealing' (DIRS) as it tracks insider/major shareholder transactions and ownership status.
2023-03-21 Korean
투자판단관련주요경영사항(파이로티닙의 제3상 임상시험계획 승인 )
Legal Proceedings Report Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding the approval of a Phase 3 clinical trial for Pyrotinib by the Ministry of Food and Drug Safety (MFDS). It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) in the Korean stock market (KOSPI/KOSDAQ). Since it is a specific regulatory disclosure regarding clinical trial status and does not fit into the other specialized categories like M&A, Earnings, or Dividends, it is classified as a general Regulatory Filing (RNS).
2023-03-21 Korean
신주인수권행사가액의조정
Share Issue/Capital Change Classification · 100% confidence The document is a regulatory filing from HLB Life Science regarding the adjustment of the exercise price of warrants (신주인수권행사가액의조정). This type of filing relates to changes in the company's capital structure and potential future share issuance due to warrant exercise price resets (refixing). It does not fit into specific categories like M&A or dividend announcements, and it is a direct disclosure of a corporate action rather than a report publication announcement. Therefore, it is classified as a Capital/Financing Update.
2023-03-14 Korean
주주총회소집결의
AGM Information Classification · 99% confidence The document is a formal notice of an upcoming Annual General Meeting (AGM) for HLB Life Science. It details the meeting date, location, agenda items (such as financial statement approval, director/auditor appointments, and business purpose changes), and information regarding electronic voting. This document serves as the official proxy solicitation and meeting notice provided to shareholders to inform them of the meeting and request their participation/votes. Therefore, it is classified as a Proxy Solicitation & Information Statement.
2023-02-24 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.